# Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

> **NCT00628095** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 100 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** CE-224,535
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00628095
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04-07
- **Primary completion:** 2009-02-04
- **Final completion:** 2009-02-04
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00628095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00628095, "Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00628095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*